Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

• ClinicalTrials.gov Identifier: NCT02851797
• Recruitment Status: Completed
• First Posted: August 2, 2016
• Results First Posted: February 2, 2023
• Last Update Posted: February 2, 2023
• Sponsor: Italfarmaco
• Collaborator: Syneos Health
• Information provided by (Responsible Party): Italfarmaco

Study Description

Brief Summary:

Primary Objective

The primary objective of the study was to establish the effects of givinostat versus placebo administered chronically over 18 months to slow disease progression in ambulant DMD subjects.

Secondary Objectives

The secondary objectives of this study were:

• To assess the safety and tolerability of givinostat versus placebo administered chronically in DMD subjects
• To evaluate the PK profile of givinostat administered chronically in DMD subjects
• To evaluate the impact on quality of life (QoL) and activities of daily living of givinostat versus placebo administered chronically.

Condition or disease	Intervention/treatment	Phase
Duchenne Muscular Dystrophy	Drug: givinostat; Drug: placebo	Phase 3

Detailed Description:

This was a phase 3, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant subjects with DMD. This study included ambulant male paediatric subjects aged ≥ 6 years at baseline affected by DMD.

A total of 179 male ambulant subjects was randomized 2:1 (givinostat: placebo).

Subjects were stratified for their concomitant use of steroids in 4 strata:

1. Deflazacort daily regimen
2. Deflazacort intermittent regimen
3. Other steroids daily regimen
4. Other steroids intermittent regimen. The study duration was planned to be 19 months.

Givinostat or placebo oral suspension (10 mg/mL) was administered orally as 2 oral doses daily while the subject were in fed state, according to the child's weight.

Study drug should have been permanently stopped if any of the following occurred:

• severe drug-related diarrhoea;
• any drug-related Serious Adverse Event;
• QTcF >500 msec;
• platelets count ≤50 x 10^9/L.
• white blood cells ≤2.0 x 10^9/L
• hemoglobin ≤8.0 g/dL

Study drug should have been temporarily stopped if any of the following occurred:

• moderate or severe diarrhoea.
• platelets count <75 x 10^9/L but >50 x 10^9/L (the treatment should been temporarily stopped and a platelets count was to be performed and re-tested until platelets normalized);
• white blood cell <3.0 x 10^9/L but >2.0 x 10^9/L (the treatment should be temporarily stopped and white blood cells had to be measured by 1 week and re-tested until white blood cells normalized);
• hemoglobin <10.0 g/dL but > 8.0 g/dL (the treatment should be temporarily stopped and hemoglobin had to be measured by 1 week and re-tested until hemoglobin normalized);
• Triglycerides >300 mg/dL (3.42 mmol/L) in fasting condition (the treatment should be temporarily stopped and triglycerides measured every 2 weeks until triglycerides returned to levels below 300mg/dL (3.42 mmol/L)

In case the study drug was temporarily stopped, the study drug could be resumed at a level 20% smaller than the one at which the Adverse Event leading to temporary stop occurred, once platelets and/or white blood cell and/or hemoglobin normalized and/or triglycerides returned to levels below 300 mg/dL (3.42 mmol/L) or diarrhoea was mild.

In addition, in case a subject had a consistent (e.g., at least 2 consecutive evaluations) platelets count ≤150 x 10^9/L and didn't meet the stopping criteria for platelets, the Investigator should have to reduce the dose by 20% of the current dose.

Only one dose reduction was allowed during the treatment period.

This trial design a single planned interim analysis. The interim was governed by an IDMC in order to solely assess futility.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 179 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
• Actual Study Start Date: June 6, 2017
• Actual Primary Completion Date: February 22, 2022
• Actual Study Completion Date: February 22, 2022

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: givinostat; Givinostat oral suspension (10 mg/mL) twice daily	Drug: givinostat; The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below: Givinostat or placebo starting dose; > or =10 and < 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid; > or =12.5 and < 20 kg: 16.7 mg bid =1.7 ml oral suspension bid; > or = 20 and < 25 kg: 20 mg bid = 2.0 ml oral suspension bid; > or = 25 and < 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid; > or = 30 and < 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid; > or = 40 and < 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid; > or = 50 and < 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid; > or = 60 and < 70 kg: 40 mg bid = 4 ml oral suspension bid; > or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid; Other Name: ITF2357
Placebo Comparator: placebo; Placebo oral suspension (10 mg/mL) twice daily	Drug: placebo; The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.

Outcome Measures

Primary Outcome Measures :

1. Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment [ Time Frame: Baseline and 18 months ]
   The time (in seconds) to climb 4 standard-sized stairs is a TFT that represents stair-climbing ability. The test was evaluated by qualified functional evaluators (ie, physiotherapists) who were different from the site personnel who reviewed subjects' safety results. The test was performed in a standardised manner described in a specific site manual. Baseline 4SC was the measurement taken at the randomization assessment, unless this was missing, in which case baseline was taken as the last non missing value recorded prior to or on the date of first study treatment. The shorter the time, the better the outcome.

Secondary Outcome Measures :

1. Mean Change From Baseline in Time to Rise From Floor After 18 Months of Treatment [ Time Frame: Baseline and 18 months ]
   An analysis of time (in seconds) to rise from the floor by change from baseline at 18 months is presented for the Target Population in the ITT analysis set. The shorter the time, the better the outcome.
2. Mean Change From Baseline in the Six-minute Walking Test (6MWT) After 18 Months of Treatment [ Time Frame: Baseline and 18 months ]

   This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.

   The 6-Minute Walk Test is a useful measure of functional capacity targeted at people with at least moderately severe impairment. A modified version of the 6MWT recommended by American Thoracic Society (2002) for use in adults was performed.

   The longer the walked distance the better the outcome.

3. Mean Change From Baseline in Total North Star Ambulatory Assessment (NSAA) Score After 18 Months of Treatment [ Time Frame: Baseline and 18 months ]
   The total North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects. The 17 items of the NSAA, ranging from standing to running 10 meters, were graded using the standard score card with each assessment rated as 0 - unable to achieve independently, 1 - modified method but achieves goal independent of physical assistance from another, or 2 - normal with no obvious modification of activity. This scale is ordinal with 0 as the minimum score (indicating full disfunctionality, i.e. the worst outcome) and with 34 as the maximum score indicating fully-independent function (the best outcome).
4. Cumulative Loss of Function on the NSAA [ Time Frame: over 18 months ]

   Subject cumulative number of failures across all postbaseline visits was the endpoint of interest for analysis.

   For each subject at each postbaseline visit, failure to perform each of the 17 items of the NSAA was assessed, where "failure" was defined as a score transition from 2 or 1 at baseline to 0 at the respective visit. The total number of failed items for the visit was calculated (maximum of 17 failed items per visit per subject). The subject's cumulative number of failures across all visits was the sum of the total failures at each postbaseline visit.

5. Mean Change From Baseline of Muscle Strength Normalized Overtime [ Time Frame: Baseline and 18 months ]
   The mean change of muscle strength normalized was evaluated by knee extension and elbow flexion normalized by subject weight, both measured by hand-held myometry (HHM).
6. Mean Change From Baseline in Vastus Lateralis Muscle Fat Fraction (VL MFF) at 18 Months [ Time Frame: Baseline and 18 months ]
   Vastus lateralis muscle fat fraction (VL MFF) was expressed as fat infiltration in this muscle. Fat infiltration was assessed by Magnetic Resonance (MRS).
7. Number of Subjects Experiencing Treatment-emergent AEs (TEAEs), Serious AEs (SAEs), Mild TEAE Moderate TEAE, Severe TEAE [ Time Frame: Baseline through end of study, that is the end of 18° month ]

   Adverse Events are unfavorable changes in health, including abnormal laboratory findings, that occur in trial participants during the clinical trial or within a specified period following the trial.

   Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.

8. Evaluation of Acceptability/Palatability of the Oral Suspension [ Time Frame: Week 4, EOS, early withdrawal ]
   Acceptability and palatability of the oral suspension over time are presented. More in details, child perception of the medicine at the three timepoints hereunder specified; parent perception of the medicine based on the child's reaction at the same three timepoints; and parent problems administering the medication at the same timepoints are reported.

Eligibility Criteria

• Ages Eligible for Study: 6 Years to 17 Years (Child)
• Sexes Eligible for Study: Male
• Gender Based Eligibility: Yes

Gender Eligibility Description

to take part in the study, subjects should be:

1) ambulant males aged ≥ 6 years at randomization with DMD-characteristic clinical symptoms or signs (eg, proximal muscle weakness, Gowers' maneuver, elevated serum creatinine kinase level) already present at screening, 2. should have a DMD diagnosis confirmed by genetic testing

• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Are an ambulant male aged ≥6 years at randomisation with DMD characteristic clinical symptoms or signs (e.g., proximal muscle weakness, Gowers' maneuver, elevated serum creatinine kinase level) already present at screening;
2. Have DMD diagnosis confirmed by genetic testing;
3. Are able to give informed assent and/or consent in writing signed by the subject and/or parent/legal guardian (according to local regulations);
4. Are able to complete 2 Four Stairs Climb test (4SC) screening assessments; the results of these tests must be within ±1 second of each other;
5. Have the mean of 2 screening 4SC assessments ≤8 seconds;
6. Have time to rise from floor between ≥3 and <10 seconds at screening
7. Have manual muscle testing (MMT) of quadriceps at screening Grade ≥- 3;
8. Have used systemic corticosteroids for a minimum of 6 months immediately prior to the start of study treatment, with no significant change in corticosteroids type or dosage or dosing regimen (excluding changes related to body weight change) for a minimum of 6 months immediately prior to start of study treatment and a reasonable expectation that dosage and dosing regimen will not change significantly for the duration of the study.
9. Subjects must be willing to use adequate contraception.

Exclusion Criteria:

1. Have exposure to another investigational drug within 3 months prior to the start of study treatment;
2. Have exposure to idebenone within 3 months prior to the start of study treatment;
3. Have exposure to any dystrophin restoration product (e.g., Ataluren, Exon skipping) within 6 months prior to the start of study treatment;
4. Use of any pharmacologic treatment, other than corticosteroids, that might have had an effect on muscle strength or function within 3 months prior to the start of study treatment (e.g., growth hormone); Vitamin D, calcium, and any other supplements will be allowed as long as their intake has been stable for 3 months prior to the start of study treatment; Testosterone will also be allowed if it is used as a replacement therapy for the treatment of delayed puberty, and testosterone dose and regimen have been stable for at least 6 months and circulating testosterone levels are within the normal ranges for the subject's age;
5. Have surgery that might have an effect on muscle strength or function within 3 months before study entry or planned surgery at any time during the study;
6. Loss of ≥30 degrees of plantar flexion from the normal range of movement at the ankle joint due to contracture (i.e. fixed loss of more than 10 degrees of plantar flexion from plantigrade, assuming normal range of dorsiflexion of 20 degrees;
7. Change in contracture treatment such as serial casting, contracture control devices, night splints, stretching exercises (passive, active, self) within 3 months prior to enrollment, or expected need for such intervention during the study;
8. Have presence of other clinically significant disease, which, in the Investigator's opinion, could adversely affect the safety of the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results;
9. Have a diagnosis of other uncontrolled neurological diseases or presence of relevant uncontrolled somatic disorders that are not related to DMD;
10. Have platelets count at screening < Lower Limit of Normal (LLN);
11. Have symptomatic cardiomyopathy or heart failure (New York Heart Association Class III or IV) or left ventricular ejection fraction <50% at screening;
12. Have a current or history of liver disease or impairment;
13. Have inadequate renal function, as defined by serum Cystatin C >2 x the upper limit of normal (ULN);
14. Have Triglycerides > 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit;
15. Have a positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus at screening15.
16. Have a baseline QTcF >450 msec, or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);
17. Have a psychiatric illness/social situations rendering the potential subject unable to understand and comply with the muscle function tests and/or with the study protocol procedures;
18. Have any hypersensitivity to the components of study medication;
19. Have a sorbitol intolerance or sorbitol malabsorption, or have the hereditary form of fructose intolerance.
20. Have contraindications to MRI or MRS (e.g., claustrophobia, metal implants, or seizure disorder).

At the discretion of the Investigator, subjects not meeting inclusion/exclusion criteria may be re-screened twice with an interval of at least 3 months between assessments.

Contacts and Locations

Locations

United States, California

Neuromuscular Research Center UC Davis Department of Physical Medicine and Rehabilitation

Davis, California, United States, 95817

Rady Children's Hospital center - UCSD Department of Neuroscience

San Diego, California, United States, 92123

United States, Colorado

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

United States, Connecticut

Connecticut Children's Medical Center - Division Neurology

Hartford, Connecticut, United States, 06106

United States, Florida

Child Health Research Institute - Department of Pediatrics

Gainesville, Florida, United States, 32610

Nemours Children's Hospital

Orlando, Florida, United States, 32827

United States, Georgia

MD Rare Disease Research, LLC

Atlanta, Georgia, United States, 30318

United States, Iowa

University of Iowa Children's Hospital

Iowa City, Iowa, United States, 52242

United States, Minnesota

University of Minnesota - Department of Neurology

Minneapolis, Minnesota, United States, 55455

United States, Missouri

Washington University School of Medicine in St Louis - Department of Neurology

Saint Louis, Missouri, United States, 63110

United States, Oregon

Shriners Hospitals for Children

Portland, Oregon, United States, 97239

United States, Pennsylvania

The Children's Hospital of Philadelphia Colket Translational Research Building

Philadelphia, Pennsylvania, United States, 19104

United States, Virginia

Virginia Commonwealth University Childrens Hospital of Richmond at Virginia Commonwealth University

Richmond, Virginia, United States, 23298

Belgium

University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology

Leuven, Belgium, 03000

Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN)

Liege, Belgium, 04000

Canada, Alberta

Kinsmen Research Centre - Alberta Children's Hospital - Alberta Health Services

Calgary, Alberta, Canada, T3B6A8

Canada, British Columbia

The University of British Columbia, Children's and Womens Health Centre of BC Branch

Vancouver, British Columbia, Canada, V6H 3V4

Canada, Ontario

Holland Bloorview Kids Rehabilitation Hospital

Toronto, Ontario, Canada, M4G1R8

France

CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest

Nantes, France, 44093

Hopital Armand Trousseau I-Motion, Plateforme d'essais cliniques pédiatriques

Paris, France, 75012

Germany

Universitatsklinikum Essen - Kinder und Jugendmedizin Neuropadiatrie

Essen, Germany, 45122

Klinik un Policlinik fur Kinder und Jugendmedizin - Universitatsklinikum Hamburg Eppendorf

Hamburg, Germany, 20246

Klinikum der Uniersitat Munchen - Campus Innenstadt

Munchen, Germany, 80337

Israel

Institute of Neurology - Schneider Children's Medical Center of Israel Kaplan, 14

Petach-Tikva, Israel, 4920235

Italy

IRCCS Istituto G.Gaslini, U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative

Genova, Italy, 16147

A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari

Messina, Italy, 98125

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica

Milano, Italy, 20122

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milano, Italy, 20133

Centro Clinico NeMO Fondazione Serena ONLUS Area SUD

Milano, Italy, 20162

Ospedale Pediatrico Bambin Gesù, Malattie Neuromuscolari e Neurodegenerative

Roma, Italy, 00146

Fondazione Policlinico Universitario "A.Gemelli", UOC Neuropsichiatria Infantile

Roma, Italy, 00168

Netherlands

Leiden University Medical Center LUMC

Leiden, Netherlands, ZH 2300 RC

Radboud University Medical Centre

Nijmegen, Netherlands, 6500

Serbia

Clinic of Neurology and Psychiatry for Children and Youth - Neurology Department Dr. Subotic 6a,

Belgrade, Serbia, 11000

Spain

Hospital Sant Joan de Déu - Neuromuscular Pathology Unit

Esplugues de Llobregat, Barcelona, Spain, 08950

Hospital Materno-Infantil - Passeig de la Vall d'Hebron

Barcelona, Spain, 08035

Hospital Universitario Virgen del Rocio

Sevilla, Spain, 41013

Hospital Universitari i Politécnic de la Fe - Servicio Neurologia

Valencia, Spain, 46026

United Kingdom

Alder Hey Children's Hospital NHS Trust

Liverpool, United Kingdom, L12 2AP

UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD

London, United Kingdom, EC1N 1EH

The John Walton Muscular Dystrophy Research Centre - Freeman Hospital - Newcastle University - Institute of Genetic Medicine

Newcastle upon Tyne, United Kingdom, NE1 3BZ

The Robert Jones and Agnes Hunt Orthopaedic Hospital - NHS Foundation Trust

Oswestry, United Kingdom, SY 10 7AG

Sponsors and Collaborators

Italfarmaco

Syneos Health

Investigators

• Principal Investigator: Eugenio Mercuri, MD, PhD; Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS

  Study Documents (Full-Text)

Documents provided by Italfarmaco:

Study Protocol  [PDF] April 8, 2020

Statistical Analysis Plan  [PDF] July 14, 2022

More Information

• Responsible Party: Italfarmaco
• ClinicalTrials.gov Identifier: NCT02851797
• Other Study ID Numbers: EPYDIS (DSC/14/2357/48); 2016-000401-36 ( EudraCT Number )
• First Posted: August 2, 2016
• Results First Posted: February 2, 2023
• Last Update Posted: February 2, 2023
• Last Verified: January 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Italfarmaco:

Dystrophy; DMD; Givinostat

Additional relevant MeSH terms:

Muscular Dystrophy, Duchenne; Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Givinostat hydrochloride; Histone Deacetylase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action